St Thomas' Hospital, London SEl 7EH
It is now well over twenty-five years since Cade (1949) published his original work on the effects of lithium salts in states of psychotic excitement. Although there is a substantial body of evidence confirming the efficacy of lithium in acute manic illness, the literature on its use as a prophylactic agent in the management of recurrent affective illnesses suggests that further study is still worthwhile (Baastrup & Schou 1967 , Coppen et al. 1971 . Schull & Sapira (1970) have emphasized the importance of strict criteria by which improvement should be judged. There is still no certainty of what constitutes a prophylactic serum lithium level, most authors accepting the assertion of Schou et al. (1970) that lithium is a prophylactic at levels in the range of 0.8-1.2 mmol/l. There is conflicting evidence concerning the effectiveness of lithium as a prophylactic agent in the schizoaffective states; Schou (1968) suggested that it is not of value, whilst found that it is.
The purpose of this study was to determine whether lithium carbonate given in whatever quantity is a useful agent in the prevention of recurrent bipolar affective, unipolar manic, or unipolar depressive states, and to define any useful prognostic factors or likely problems which might occur in patients taking a salt acknowledged to have a low therapeutic index, for a prolonged period of time, as evidenced by Fry & Marks (1971) and Crammer et al. (1974) .
Methods
The Psychiatric Department at St Thomas' Hospital has always managed to attract patients who, having derived benefit from the treatment of acute mental illness, have faithfully attended follow-up clinics for many years. This has been particularly true of those suffering from affective disorders. This paper is a longitudinal study of 100 patients randomly selected from a much larger number who were treated with lithium carbonate at this hospital exclusively. The main selection criteria were that the patients suffered from recurrent disorders of affect and that their lithium treatment throughout was controlled at the lithium clinic at the hospital. Selection of patients for lithium treatment per se was to a large extent performed independently by the referring psychiatrist.
None of the patients included in the series had a history of recurrent affective illness of less than five years; the mean duration before starting lithium was 10 years. An assessment was made ofeach patient's psychiatric state over the five years before taking lithium, and during the five years after starting the drug. Patients were used as their own controls, and by this means the pitfalls of placebo studies may have been avoided.
The aim of the clinic included an attempt to give the patients maximum benefit from lithium over a prolonged period of time. This required much support and encouragement, but the result was that it was possible to maintain the large majority of patients on lithium for many years. The problem of differential drop-out of patients, depending on the benefit or otherwise which the patients felt that they were obtainingfrom the drug, was considered. Prior clinical impressions had suggested that this might not be a problem and the subsequent results in the random sample confirmed this, since only one patient had to be excluded from the analysis. The final total of 99 patients thus provided an opportunity to study a relatively un selected sample throughout five years' continual treatment with lithium.
Although we accepted the views of several workers , Angst & Perris 1968 , Rennie 1942 , Kirchhof 1942 concerning the natural history of affective disorders -for example, the genetic dichotomy between bipolar and unipolar affective psychoses; the increasingly frequent and rapid pathological mood swings in bipolar as compared with unipolar i11nesses; and alterations in probabilities offirst attacks at different ages -we felt that the within-patient control design would provide valuable additional information about identifying factors that would indicate which types of individual are likely to respond to lithium. Also, it was felt that this method provided an opportunity to control for other possible sources of selection bias and for investigation of other fluctuations in natural history. For example, some patients may have been doing well on other medication anyway, in which case the effects of the exhibition of lithium would be minimal. Conversely, patients may have been referred at times of high frequency of attacks which may have preceded a naturalremission, in which case a generalized positive response to the drug would be expected throughout the series. It is emphasized that, despite these qualifications, this study above all gives an opportunity to compare the characteristics of those patients whose clinical state had improved after five years' lithium treatment with the characteristics of those who had not.
All received lithium carbonate in divided doses by day or as a sustained-release tablet given at night. Other methods of treatment were used as considered necessary by the physician in charge of the clinic. Blood was taken for serum level estimation by flame photometer at random times ofday during the week preceding visits to the clinic, which took place at monthly intervals for each patient.
The patients' notes were reviewed and an appraisal of various parameters made. Those of particular relevance were: (I) diagnosis; (2) age; (3) sex; (4) family history of affective illness; (5) presence or absence of easily understandable precipitating factors; (6) treatment variables, such as concomitant use of other physical methods; (7) serum lithium levels; (8) admissions to hospital here or elsewhere; (9) suicide attempts; (10) episodes of i11ness, including cycle, interval and episode lengths as defined by Baastrup & Schou (1967) . These variables were chosen to provide the most rigorous criteria for defining the population and the events occurring in it. This was important since the study was retrospective; for example, episodes of i11ness were included only if they were firmly diagnosed by the clinician at the time. Transient alterations in mood reported by the patient and recorded in the contemporary notes were thought to be less reliable and such information has been omitted from this study.
Resultsand discussion
A comparison of illness events occurring in the five years before and the five years after starting lithium is i11ustrated in Table I . The number of attacks of depression was significantly reduced although the concomitant prescription of antidepressant drugs was not. This confirms the work of Zall et al. (1968) , Himmelhoch et al. (1972) and Lingjaerde et al. (1974) . The number of attacks of hypomania did not diminish, neither did the prescription of antimanic drugs. The decrease in the number of electroplexies (ECT) given throughout the group was significant and reflects the findings of Coppen et al. (1971) and may well be evidence of overall attenuation, although we hesitate to draw inferences concerning the outcome in mania and depression separately since ECT has long been used in the treatment of both conditions at this hospital. Twice as many people showed a decrease in the number of suicide attempts than showed an increase but this difference did not reach significance. Cycle length was significantly increased, and analysis by interval and episode lengths revealed that episodes, when they occurred, lasted the same length of time as previously, but that the interval between episodes was significantly increased. This is a different finding from that of Baastrup & Schou (1967) . Table 2 shows the sample divided into responders and non-responders broken down by diagnosis. Responders are those patients showing an excess of changes of the events listed in Table 1 in a direction suggesting alleviation of illness -for example, a decrease in ECT, an increase in cycle length, etc. Patients showing an excess of individual changes in the opposite direction are designated as non-responders. The diagnostic categories are those of the International Classification of Diseases with the exception of 'Bipolar Affective II' which we have taken to mean those patients who experience their first attack of mania during treatment of depression by ECT or antidepressant drugs. This is not as defined by Fieve et al. (1976) who highlighted the confusion that exists in the literature concerning this diagnostic category. We suggest that it would be reasonable to use the term bipolar affective psychosis fJ for this group to avoid further confusion. From Table 2 it can be seen that there is a significant tendency for the unipolar depressive and bipolar groups to respond to lithium, and for the depressive neurosis, personality disorder (affective), and schizoaffective groups to be unresponsive to lithium. If the binomial test is used, the significance is confirmed, especially for the unipolar depressives and bipolar affectives who tend to respond, and for the depressive neurosis and schizoaffective groups who tend not to respond. The numbers in the three remaining groups were too small for individual analysis by this method. Thus it would appear that two-thirds of the patients in the affective-psychotic groups responded but not one of the non-psychotic patients seemed to benefit. The results in the schizoaffective group confirm Schou's work but not that of and Sargant (1977) . We next examined other factors in the two outcome groups, some of which are summarized in Table 3 . Responders tended to be about 5t years older, on average, than non-responders, both in age at onset and in age at presentation at the hospital. This difference, although large, is not significant because of the large age scatter. There was no sex difference in outcome or diagnostic category. However, a positive family history is related to a positive response to treatment, confirming the observations of Prien ct al. (1974) . The relationship between 'understandable' precipitating causes and outcome is of interest, there being a significant relationship between the occurrence of such events and a poor response to prophylactic lithium, which is in agreement with the work of Goodwin et al. (1972) . We may thus speculate that lithium is most elTective in the endogenous alTective psychoses. Lastly, all the data on serum lithium estimations. were collected for the series. The dilTerence in mean serum level between responders and non-responders was significant (P < 0.02). This confirms the importance of maintaining a so-called 'therapeutic level' in the blood. However, we were interested to see the relatively low serum lithium levels obtained. This seems to cast doubt on the customarily recommended range of 0.8-1.2 mmol/l, It may well be that such figures were arrived at simply by extrapolation from inpatient treatment of acutely manic patients who responded only to relatively high blood levels. From our data it would seem reasonable to suggest that a prophylactic serum lithium range could be 0.5-0.9 mmol/l. We confirmed the incidence of other biological elTects usually considered as unwanted elTects. Nausea occurred in 5%, diarrhoea in 3%, thyroid dysfunction in 4% (myxoedema 1%, thyrotoxicosis 1%. and nontoxic goitre 2%).oedema in 3%, polyuria in 5%,and fine and coarse nonspecific tremors in 8°O' Definite extrapyramidal syndromes occurred in 2 patients, both of whom were over the age of 65. This effect proved irreversible. These patients could well have been constitutionally vulnerable. With the exception of the extrapyramidal syndromes and polyuria, all the side effects appeared to be related to high blood levels.
A comment must be made about the relative efficacy of lithium in unipolar as opposed to bipolar psychoses. The burden of evidence to date suggests that it is more elTective in preventing bipolar illness. However, the present series appears to show that there is no dilTerence and that lithium is equally elTective in both groups. Although our findings suggest that there was no overall change in the incidence of manic attacks, we had the clinical impression that these attacks were attenuated in severity. Much of the improvement seen in bipolar patients, however, would seem to be due to the definite lowered frequency of depressive attacks. This view is supported by the decreased use of ECT overall.
Summary
Lithium carbonate is a useful agent in the prophylaxis of recurrent affective disorders in the psychotic (unipolar or bipolar) as opposed to the neurotic, personality disordered, or schizoaffective groups. A good outcome is related to a positive family history of affective disorder, and to the absence of precipitating causes for illness episodes. The importance of serum lithium measurement is confirmed, but it is suggested that a prophylactic serum level range could be 0.5-0.9 mmol/l, Caution is recommended in the treatment of the elderly by this means because of the increased incidence of unwanted effects.
